Vioquest Pharmaceuticals, Inc. - Current report filing (8-K)
16 September 2008 - 5:35AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(
d
)
OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): September 12, 2008
VioQuest
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-16686
|
58-1486040
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
180
Mt. Airy Road, Suite 102
Basking
Ridge, NJ 07920
(Address
of principal executive offices)
(908)
766-4400
(Registrant's
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
|
Item
1.01
|
Entry
into a Material Definitive
Agreement.
|
On
September 12, 2008, VioQuest Pharmaceuticals, Inc. (the “Company”) executed a
secured promissory note (the “Note”) payable to Morgan, Lewis & Bockius, LLP
(“MLB”), the Company’s legal counsel with respect to intellectual property
matters, for $527,849.50 representing outstanding legal fees and related
expenses owed by the Company to MLB. The Note becomes due and payable upon
the
earlier of (a) certain liquidity events, including the receipt of funds from
the
Company’s sale of Unused Net Operating Losses (“NOL’s”) Carryover under the New
Jersey Economic Development Authority’s Technology Business Tax Certificate
Transfer Program, or (b) December 31, 2008 and is secured by any proceeds from
such sale of NOL’s. The note does not bear interest.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
|
|
10.1
|
Secured
Promissory Note dated September 12, 2008 granted to Morgan, Lewis
&
Bockius, LLP.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
|
|
VioQuest
Pharmaceuticals, Inc.
|
|
|
|
|
Date: September
15, 2008
|
By:
|
/s/ Christopher
P. Schnittker
|
|
|
Christopher
P. Schnittker
|
|
|
Vice
President &
Chief
Financial Officer
|
VioQuest Pharmaceuticals (CE) (USOTC:VOQP)
Historical Stock Chart
From Oct 2024 to Nov 2024
VioQuest Pharmaceuticals (CE) (USOTC:VOQP)
Historical Stock Chart
From Nov 2023 to Nov 2024
